# To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

> **NCT04796922** · PHASE3 · WITHDRAWN · sponsor: **Incyte Corporation**

## Conditions studied

- Follicular Lymphoma ( FL)
- Marginal Zone Lymphoma (MZL)

## Interventions

- **DRUG:** parsaclisib
- **DRUG:** rituximab
- **DRUG:** obinutuzumab

## Key facts

- **NCT ID:** NCT04796922
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12-30
- **Primary completion:** 2028-12-20
- **Final completion:** 2032-08-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was withdrawn due to a business decision.
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796922, "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04796922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*